Our Clinical Trials

IPL344 for ALS

ipl344 als iplIPL344 has entered a phase 1/2a, open-label, dose-escalating study with amyotrophic lateral sclerosis (ALS) patients to assess the safety, tolerability and pharmacokinetics of intravenously administrated IPL344. By the end of this study, the participants will continue to a follow-up, open-label, phase 2 study. The study will begin in the ALS Clinic of the Neurology Department of Hadassah Medical Center in Jerusalem, Israel.